You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
NYAB Q3’24: Continued growth ahead
NYAB's Q3 numbers were below our expectations in terms of timing of revenue, but otherwise as expected. The order book is at a record level and the margin development continued positively.
Continued growth ahead! Analyst Aapeli Pursimo summarizes.
See the Q3 CEO-interview:
NYAB Q3´24: Strong order backlog
Read the latest research, published 11/7/2024:
NYAB Q3'24: Well positioned for future growth
Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024
Aiforia as an Investment | Life Science Night Dec. 2, 2024
Faron Pharmaceuticals as an Investment | Life Science Night Dec. 2, 2024
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Life Science Night | December 2, 2024
View all videos